ClinicalTrials.gg
Status unknownNCT01742533Updated Dec 5, 2012

Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure

A Phase 1/2 interventional study of human umbilical cord mesenchymal stem cells and hUCMSCs and hCBMNCs in Premature Ovarian Failure,, sponsored by Shenzhen Beike Bio-Technology Co., Ltd.. Status unknown at 1 site in China. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2012-12-05.

Sponsored by Shenzhen Beike Bio-Technology Co., Ltd. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2012), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Primary Ovarian Insufficiency with a site in China — 14 open to participants now, 16 under way, none of them phase 3. Primary Ovarian Insufficiency · China.

Planned enrollment
19th of 27
40 · median 50
Started
2012
with 1 other
Phase 1/2
8 of 40
2 open now
Registered
1st of 40
by date

Among the 40 studies in Primary Ovarian Insufficiency with a site in China, this one is the 19th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2012, is one of 8 in phase 1/2, and was the 1st registered.

Primary Ovarian Insufficiency

181 studies on the registry are indexed under Primary Ovarian Insufficiency; 48 are open to participants now.

Browse Primary Ovarian Insufficiency studies →

Open to participants now

14 of the 40 studies in Primary Ovarian Insufficiency with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Primary Ovarian Insufficiency studies recruiting now, 1 (4%) sets no upper age limit and 24 (89%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 39 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Primary Ovarian Insufficiency with a site in China, or all of them as a file.
02

Study summary

Premature ovarian failure (POF) refers the occurrence of amenorrhoea, elevated serum gonadotrophins and hypoestrogenism levels in female before the age of 40. It has important physical and psychological consequences/impact in those patients.

Premature ovarian failure (POF) is currently managed by non-physiological sex steroid regimens which are inadequate at optimizing uterine characteristics.

Human umbilical cord mesenchymal stem cells (hUCMSCs) and human cord blood mononuclear cells (hCBMNCs) have been shown to have the ability to modulate the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy for POF.

In this study, the safety and efficacy of hUCMSCs and hCBMNCs transplantation combined with Hormone Replacement Therapy will be evaluated in patients with Premature Ovarian Failure. Participants will be followed for an expected average of 48 weeks.

03

Conditions studied

  • Premature Ovarian Failure,

Keywords

  • Hormone Replacement Therapy,
  • Premature Ovarian Failure,
  • Stem Cell Therapy
04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between age 18- 39 years, Female only.
  • Diagnosed with Premature Ovarian Failure,and currently receiving Hormone Replacement Therapy;
  • Willing to sign the Form.

Exclusion criteria

Exclusion Criteria:

  • Fragile X chromosome.
  • polycystic ovary syndrome.
  • +.
  • disease, e.g. lupus erythematosus, multiple sclerosis.
  • Severe pulmonary and hematological disease, or hypo-immunity.
  • Currently undertaking other treatment that may affect the safety/efficacy of stem cells.
  • Pregnancy or lactation
  • Enrollment in other trials in the last 3 months. • Other criteria the investigator consider improper for inclusion.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Group1 : HRT plus hUCMSCs treatment:

    Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.

    Biological: human umbilical cord mesenchymal stem cells

  • Experimental
    Group 2: HRT plus hCBMNCs and hUCMSCs therapy

    Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.

    Biological: hUCMSCs and hCBMNCs

  • Experimental
    Group3 : HRT plus hCBMNCs treatment:

    Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.

    Biological: human cord blood mononuclear cells

  • Experimental
    Group 4:Hormone Replacement Therapy

    Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up.

    Drug: Hormone Replacement Therapy

Interventions

06

What researchers measure

Primary outcomes

  1. Serum Level of follicle-stimulating hormone

    Time frame: 48 weeks after treatment

Secondary outcomes

  1. Uterine and Ovary characteristics of B ultrasound, including Uterine/Ovarian size and Blood Flow

    Time frame: 48 weeks after treatment

  2. Modified Kupperman Score

    Time frame: 48 weeks after treatment

  3. Incidence of Adverse Events and Serious Adverse Events

    Time frame: 48 weeks after treatment

07

Study locations

1 of 1 sites recruiting
  • Shenzhen People's Hospital
    Shenzhen, Guangdong 518020, China
    Recruiting
    • Fangming Su · Contactsfmlxq@163.com · 86-755-25533018
    • Fangming Su · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Jun 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2012
First posted
Dec 5, 2012
Start
Mar 2012
Primary completionEst.
Jun 2013
CompletionEst.
Mar 2014
Last update
Dec 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01742533
Lead sponsor
Shenzhen Beike Bio-Technology Co., Ltd.
Responsible party
Sponsor
First posted
Dec 5, 2012
Start date
Mar 2012
Primary completion
Jun 2013 (estimated)
Completion
Mar 2014 (estimated)
Last update
Dec 5, 2012

Study contacts

FangMing Su, Master
Contact
sfmlxq@163.com
86-755-25533018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion